Prodotti competitors / Area Kite
Imbruvica: Withdrawal of the application to change the marketing authorisation
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
Janssen-Cilag International N.V. withdrew its application for the use of Imbruvica in combination with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma (MCL, a cancer of a type of white blood cell called B cells).
The company withdrew the application on 13 December 2022.
More information are available at EMA website page
Grazie per il tuo feedback!